New Mexico Cancer Care Alliance

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2002-01-01

Employees: 11

Market Cap: -

Website: https://nmcca.org

Clinical Trials

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Velcade and Sorafenib

First Posted Date: 2010-04-08

Last Posted Date: 2015-09-17

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 17

Registration Number: NCT01100242

Locations: 🇺🇸
Memorial Medical Center- Cancer Center, Las Cruces, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sorafenib & Capecitabine

First Posted Date: 2009-12-16

Last Posted Date: 2021-06-02

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 15

Registration Number: NCT01032850

Locations: 🇺🇸
Cancer Center at Presbyterian Hospital, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States

Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

Phase 2

Terminated

Conditions: Liver Cancer

Interventions: Radiation: Tomotherapy treatment

First Posted Date: 2009-12-11

Last Posted Date: 2015-07-07

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 2

Registration Number: NCT01030757

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Imatinib mesylate
Drug: Paclitaxel

First Posted Date: 2009-11-11

Last Posted Date: 2015-07-03

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 34

Registration Number: NCT01011075

Locations: 🇺🇸
Univ. of Washington Fred Hutchinson Cancer Research Center (UW-FHCRC), Seattle, Washington, United States
🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Phase 2

Withdrawn

Conditions: Chronic Myelogenous Leukemia

First Posted Date: 2009-11-11

Last Posted Date: 2011-09-27

Lead Sponsor: New Mexico Cancer Care Alliance

Registration Number: NCT01011998

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Comparison of Standard of Care or Treatment on Protocol

Not Applicable

Terminated

Conditions: Ovarian Cancer
Stomach Cancer
Esophageal Cancer
Uterine Cancer
Skin Cancer
Lung Cancer
Bladder Cancer

Interventions: Other: standard of care

First Posted Date: 2009-11-10

Last Posted Date: 2013-08-14

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 13

Registration Number: NCT01010334

Locations: 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Paclitaxel, carboplatin, temozolomide

First Posted Date: 2009-11-06

Last Posted Date: 2017-10-18

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 19

Registration Number: NCT01009515

Locations: 🇺🇸
Hematology Oncology Associates, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma

Interventions: Drug: Erlotinib
Drug: Temsirolimus

First Posted Date: 2009-11-06

Last Posted Date: 2015-08-10

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 13

Registration Number: NCT01009203

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico Cancer Center @ Lovelace Medical Center, Albuquerque, New Mexico, United States

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Advanced Solid Tumor Malignancies

Interventions: Drug: 5-azacytidine, erlotinib
Drug: Erlotinib PO and Vidaza IV

First Posted Date: 2009-10-16

Last Posted Date: 2013-05-01

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 30

Registration Number: NCT00996515

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma

Terminated

Conditions: Melanoma

First Posted Date: 2009-10-16

Last Posted Date: 2015-06-18

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 100

Registration Number: NCT00996827

Locations: 🇺🇸
Lovelace Women's Hospial, Albuquerque, New Mexico, United States
🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy